Johnson & Johnson (JNJ) is Cigna Investments Inc. New’s 8th Largest Position

Cigna Investments Inc. New reduced its stake in Johnson & Johnson (NYSE:JNJ) by 5.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,075 shares of the company’s stock after selling 6,906 shares during the period. Johnson & Johnson makes up 1.0% of Cigna Investments Inc. New’s portfolio, making the stock its 8th biggest position. Cigna Investments Inc. New’s holdings in Johnson & Johnson were worth $15,091,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in JNJ. Korea Investment CORP lifted its holdings in shares of Johnson & Johnson by 38.9% during the first quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock valued at $265,296,000 after purchasing an additional 596,134 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Johnson & Johnson by 1.2% during the first quarter. Fisher Asset Management LLC now owns 11,093,898 shares of the company’s stock valued at $1,381,745,000 after purchasing an additional 136,764 shares in the last quarter. BTR Capital Management Inc. lifted its holdings in shares of Johnson & Johnson by 2.7% during the first quarter. BTR Capital Management Inc. now owns 99,020 shares of the company’s stock valued at $12,333,000 after purchasing an additional 2,626 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co lifted its holdings in shares of Johnson & Johnson by 1.5% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 69,707 shares of the company’s stock valued at $8,682,000 after purchasing an additional 1,007 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Johnson & Johnson by 12.7% during the first quarter. Janney Montgomery Scott LLC now owns 768,335 shares of the company’s stock valued at $95,696,000 after purchasing an additional 86,458 shares in the last quarter. 65.61% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) is Cigna Investments Inc. New’s 8th Largest Position” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.truebluetribune.com/2017/11/20/johnson-johnson-jnj-is-cigna-investments-inc-news-8th-largest-position.html.

Johnson & Johnson (NYSE JNJ) opened at $138.00 on Monday. The firm has a market capitalization of $370,739.75, a P/E ratio of 19.33, a price-to-earnings-growth ratio of 2.80 and a beta of 0.82. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.68 EPS. equities research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.43%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

A number of research analysts have weighed in on the company. J P Morgan Chase & Co increased their target price on Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 target price on Johnson & Johnson and gave the company a “hold” rating in a report on Tuesday, August 15th. Vetr downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price on the stock. in a report on Monday, September 18th. Stifel Nicolaus increased their target price on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a report on Wednesday, October 18th. Finally, Citigroup Inc. increased their target price on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a report on Monday, October 23rd. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $143.70.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply